Naviter Wealth LLC Sells 193 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Naviter Wealth LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,223 shares of the medical research company’s stock after selling 193 shares during the period. Naviter Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,181,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TMO. WCM Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after acquiring an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. raised its position in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after buying an additional 1,654 shares in the last quarter. DMC Group LLC lifted its stake in Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after purchasing an additional 84 shares during the last quarter. S. R. Schill & Associates boosted its position in Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after buying an additional 792 shares during the period. Finally, Check Capital Management Inc. CA purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth about $219,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.7 %

TMO stock opened at $573.06 on Tuesday. The company has a market capitalization of $218.74 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 2.41 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business has a 50 day simple moving average of $574.18 and a two-hundred day simple moving average of $531.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,277 shares of company stock worth $29,649,264. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Royal Bank of Canada upped their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. HSBC boosted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $606.76.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.